Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
116,964,738
-
Total 13F shares
-
49,467,518
-
Share change
-
+2,562,125
-
Total reported value
-
$435,305,054
-
Put/Call ratio
-
98%
-
Price per share
-
$8.80
-
Number of holders
-
92
-
Value change
-
+$17,238,403
-
Number of buys
-
49
-
Number of sells
-
39
Institutional Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q4 2017
As of 31 Dec 2017 Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) had 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 49,467,518 shares of stock of the company.
Largest 10 holders included WELLINGTON MANAGEMENT GROUP LLP, FMR LLC, Temasek Holdings (Private) Ltd, BlackRock Inc., Kohlberg Kravis Roberts & Co. L.P., STATE STREET CORP, JPMORGAN CHASE & CO, Vanguard Group Inc, CITADEL ADVISORS LLC, and ORBIMED ADVISORS LLC.
This table shows 92 institutional shareholders of the security as of 31 Dec 2017.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.